Globus Medical (GMED) Tops Q1 EPS by 2c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Globus Medical, Inc. (GMED) Reports Revenue Well Above Consensus, Brean Capital Note; PT to $33
May 6, 2015 7:13 AM EDTBrean Capital reiterates their Buy rating on Globus Medical, Inc. (NYSE: GMED) and raised the target price to $33 (from $30) after GMED posted revenues well above consensus. GMED's 1Q15 report showed and increase of 15.2% in revenues to $131.6 million. Despite lower margins, new products and... More
